Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
28 hedge funds and large institutions have $527M invested in Sinovac Biotech, Ltd in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1% more capital invested
Capital invested by funds: $522M → $527M (+$4.85M)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$110K |
SVA Hedge Fund Activity: Q2 2021 in Review
28 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2021, worth a combined $527M — up 0.93% from $522M a quarter earlier.
Fund positioning in SVA was balanced in Q2 2021: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.73K. The largest seller was Freedom Investment Management, cutting an estimated $110K.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $527M of Sinovac Biotech, Ltd stock for Q2 2021, up 0.93% quarter-over-quarter.
- 1 fund opened new Sinovac Biotech, Ltd positions in Q2 2021 and 1 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2021 was Morgan Stanley, an estimated $8.73K added.
- The largest Sinovac Biotech, Ltd seller in Q2 2021 was Freedom Investment Management, an estimated $110K sold.
Based on aggregated 13F filings for Q2 2021.